Acupuncture May Reduce the Need for Formula Feeding in Mothers After Cesarean Delivery: Secondary Analysis of the Data from a Randomized Clinical Trial.

Breastfeed MedJul 29, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Taras I Usichenko, Judith Aselmeyer, Martin A Feig et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of a randomized controlled trial evaluated the impact of acupuncture on formula feeding needs in 180 mothers post-cesarean delivery. Results indicated that mothers receiving acupuncture had a significantly shorter median duration of additional formula feeding (3 days) compared to those receiving placebo (4.5 days, p < 0.001) and standard care (5 days, p = 0.006).

Key findings

  • Median duration of additional formula feeding was 3 days for acupuncture vs 4.5 days for placebo (p < 0.001).
  • Median duration of additional formula feeding was 3 days for acupuncture vs 5 days for standard care (p = 0.006).
  • Newborns' mean weight decreased by 6.2% on days 2 and 3 post-cesarean delivery (p < 0.02).

Why it matters

Understanding the potential benefits of acupuncture in reducing formula feeding can inform postpartum care strategies for mothers after cesarean delivery, promoting breastfeeding and potentially improving neonatal outcomes.

Source

PubMed · PMID 42528319

Published in Breastfeed Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.